Lilly drops the Nectin4 ADC (LY4101174) with an enrollment of 143 globally.
ChinaCT
Lilly drops the Nectin4 ADC (LY4101174) with an enrollment of 143 globally. #Lilly #Pfizer #Seagen
PCC Study Result
Astellas Pharma has terminated the first-in-human study (NCT06544642) of its STING inhibitor ASP5502—an AI-derived PCC that moved from design to clinic in just 7 months. Speed is improving, but translation remains the real bottleneck.
VX-993’s removal from Vertex’s pipeline was not a sudden decision, but the endpoint of a visible retreat, once positioned as an injectable follow-on candidate. The asset first failed to meet the primary endpoint in Phase 2 acute pain, then lost its role in Vertex’s broader pain expansion strategy as the company narrowed its focus, and has now been effectively pushed out of the pipeline altogether. From trial failure, to strategic narrowing, to final removal, the path was fairly clear.
VX-993’s removal from Vertex’s pipeline was not a sudden decision, but the endpoint of a visible retreat, once positioned as an injectable follow-on candidate.
Pipeline
Merck has discontinued development of the PARP1i M9466 (HRS-1167), which it had licensed from Hengrui. In a Ph1 study evaluating the combination with irinotecan in CRC, the program encountered DLTs. Against this backdrop, the planned expansion into SCLC was not pursued further.
Merck has discontinued development of the PARP1i M9466 (HRS-1167), which it had licensed from Hengrui. In a Ph1 study evaluating the combination with irinotecan in CRC, the program encountered DLTs. Against this backdrop, the planned expansion into SCLC was not pursued further.
REGN5381 Hypertension Trial Terminated
Regeneron Pharmaceuticals has discontinued the Phase 2 NATRIX-SBP study (NCT06833190) evaluating REGN5381 in uncontrolled hypertension. The trial enrolled 34 pt before termination.
This marks the 2nd MNC to abandon this target, following Novartis's earlier exit.
Betta Pharma Files for Hong Kong IPO, Valued at RMB 24.5B on SZSE
Betta Pharma Files for Hong Kong IPO, Valued at RMB 24.5B on SZSE
Sirius Therapeutics Files for Hong Kong IPO, With Two siRNA Phase 2 Assets Targeting FXI and Lp(a).
Sirius Therapeutics Files for Hong Kong IPO, With Two siRNA Phase 2 Assets Targeting FXI and Lp(a).
CTTQ has submitted an ANDA for fruquintinib (Fruzaqla) in China, possibly in preparation for market entry after the patent expires in 2028.
CTTQ has submitted an ANDA for fruquintinib (Fruzaqla) in China, possibly in preparation for market entry after the patent expires in 2028. Tables might turn — will CTTQ's Anlotinib be next? $HCM $TAK
Novartis filed an IND application for PKN605 in patients with atrial fibrillation in China, aiming to enhance its presence in the cardiovascular area.
Novartis Seeks IND Clearance for PKN605 in China. #Novartis #PKN605 #AF
Bayer has filed the NDA for the HER2 inhibitor BAY 2927088 in China, with both Breakthrough Therapy Designation (BTD) and priority review status, just two months after the U.S. submission.
Bayer Files HER2i BAY 2927088 NDA in China. #Bayer #HER2 #China
BeOne has terminated the clinical trial of DGKζ inhibitor BGB-30813 due to safety concerns, following a study halt last year. The compound would likely be removed from the pipeline, despite its inclusion in the R&D Day presentation just last month.
BeOne has terminated the clinical trial of DGKζ inhibitor BGB-30813 due to safety concerns.
Sunho initiates a Phase II/III trial of IBB0979 (a B7-H3/IL-10 immunocytokine) combined with topotecan versus topotecan alone in relapsed small cell lung cancer, targeting enrollment of 200 patients.
IBB0979 enters Phase II/III study in relapsed SCLC, combo with topotecan. #SUNHO
BMS has filed its first China IND for BMS-986340 (Acceptance No. JXSL2500124), aiming for future development.
BMS has submitted its first IND application in China for BMS-986340, an investigational anti-CCR8 monoclonal antibody. $BMY $ZLAB $ONC
Puhe Biopharma Submits IND Application in China for WRN Inhibitor PH027 Targeting MSI-H Tumors. $NVS $GSK $RHHBY
FrontPage
Pipeline
Valuation
Hemay Pharmaceutical Files for Hong Kong IPO After 3.9B RMB Valuation in December Round
Beigene temporarily halted the first-in-human trial of BGB-A3055 (#CCR8) due to a sponsor decision, not a change in the safety or benefit-risk balance. Last November, Zai Lab also halted its anti-CCR8 antibody ZL-1218 due to safety reasons.
Frontpage
Pipeline
Valuation
Insilico Medicine files for a Hong Kong IPO, with its latest post-money valuation at $1.331 billion.
HER2-DAC TERMINATION
Orum Therapeutics discontinued HER2-DAC development after an internal assessment of its clinical status. #degrader
First page
Pipeline
Valuation
Suzhou Ribo Life Science (瑞博生物) files for a Hong Kong IPO with a post-Series E2 financing valuation of 4.8 billion RMB.
The next generation anti-nectin-4 ADC LY4052031 study (NCT06465069) is on hold because Eli Lilly called it off. It's about advanced urothelial or other solid tumors.
Live now meetings.asco.org/abstracts-pr...
#ASCO25 release abstract titles today. Meeting.asco.org
SpringWorks Pipeline
MapKure, a joint venture between SpringWorks and BeiGene, has officially terminated the development of its RAF dimer inhibitor BGB-3245 (brimarafenib) following a funding halt driven by strategic business considerations. $SWTX $ONC
Merck has suspended the Phase 1 trial of #M5542, a CD80, CD86, and OX40L antagonist developed for autoimmune diseases, citing sponsor-related reasons. #NCT06577337
Mabwell (Shanghai) Bioscience has applied for an IPO in Hong Kong.
Hengrui Pharmaceuticals files for the Hong Kong IPO.
Due to a business decision, Astellas terminated the phase 1 study of CD20 autologous convertible CAR-T ASP2802. #NCT06248086 #Xyphos
Haixi Pharmaceuticals files for HONG KONG IPO.
